[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"traditional-chinese-medicine-tcm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:traditional-chinese-medicine-tcm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,75,99,125,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100640297","phase-2-spatiotemporal-evolution-of-traditional-chinese-medicine-mechanisms-in-acute-ischemic-stroke-treated-with-dengzhan-xixin-and-dengzhan-shengmai-100640297",false,"NCT07591883","Spatiotemporal Evolution of Traditional Chinese Medicine Mechanisms in Acute Ischemic Stroke Treated With Dengzhan Xixin and Dengzhan Shengmai","STEM-DZ","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Meeting the diagnostic criteria for acute ischemic stroke in accordance with the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2023\n3. Within 48 hours after the first onset\n4. National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 25 points\n5. Voluntarily signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-stroke modified Rankin Scale (mRS) score ≥ 2\n2. Patients with transient ischemic attack (TIA), complicated with cerebral hemorrhage or subarachnoid hemorrhage\n3. patients with brain tumor, Alzheimer's disease, psychosis, or a confirmed diagnosis of dementia\n4. Patients undergoing endovascular thrombectomy\n5. Patients with severe cardiac diseases such as valvular heart disease, infective endocarditis, myocardial infarction, heart failure, severe hepatic or renal insufficiency, respiratory failure, malignant tumor, or massive gastrointestinal hemorrhage\n6. Patients who have used any preparations containing the same ingredients as the study drug (e.g., Erigeron breviscapus, ginseng, dwarf lilyturf tuber, schisandra chinensis, etc.) within the past 2 weeks\n7. Patients with a history of allergy to the study drug or preparations containing the same ingredients\n8. Pregnant or lactating women\n9. Patients judged by the investigators as unsuitable for participation in this trial.","ALL","18 Years",{"count":19,"type":20},358,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","To integrate large-scale RCT data on clinical symptoms, TCM syndromes, prognosis, and multi-omics profiles, construct a spatiotemporal dynamic network for disease-syndrome evolution of acute ischemic stroke (AIS) in the acute and recovery phases, evaluate the efficacy and safety of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS, and provide evidence for precise syndrome differentiation and individualized therapy.Secondary Objective:To investigate the optimal time window and key intervention targets of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS.",[27,28,29],"Ischemic Strokes","Traditional Chinese Medicine (TCM)","Prognosis",[31,28,32,33],"Ischemic Stroke","Dianzhizhengmai Capsules","Dengzhanxixin Injection","NOT_YET_RECRUITING","2026-05-11",{"date":37,"type":38},"2026-05-18","ACTUAL",{"date":40,"type":20},"2026-06-01",{"date":42,"type":20},"2029-07-31",{"name":44,"class":45},"Guangdong Provincial Hospital of Traditional Chinese Medicine","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100622177","efficacy-and-safety-of-qibei-jiedu-formula-for-preventing-and-managing-acute-radiation-dermatitis-in-breast-cancer-patients-100622177","NCT07380230","Efficacy and Safety of Qibei Jiedu Formula for Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients","Efficacy and Safety of Qibei Jiedu Formula Versus Placebo in Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients: A Prospective, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with pathologically confirmed unilateral stage I-III non-inflammatory breast cancer, having undergone breast-conserving surgery or modified radical mastectomy, and having received or planned to receive standard adjuvant therapy according to current clinical guidelines.\n* Scheduled to receive postoperative adjuvant radiotherapy using a hypofractionated regimen (40-50 Gy\u002F15 fractions) as recommended by the NCCN Breast Cancer Guidelines and the CSCO Breast Cancer Diagnosis and Treatment Guidelines (2024 Edition).\n* Meeting the TCM diagnostic criteria for the syndrome of Qi-Yin Deficiency with Blood Stasis and Toxin Accumulation.\n* Karnofsky Performance Status (KPS) score ≥70.\n* Age ≥18 years, female.\n* Voluntarily participating in the study and providing written informed consent.\n\nExclusion Criteria:\n\n* Presence of grade 4 radiation dermatitis requiring urgent intervention at enrollment or during the study.\n* Prior radiotherapy to the breast or chest within the past 3 months.\n* Any skin condition that may interfere with the assessment of radiation dermatitis, such as active infection, atopic dermatitis, psoriasis, vitiligo, active collagen vascular disease (e.g., scleroderma, lupus erythematosus), or other known autoimmune disorders significantly altering skin appearance or physiological response.\n* Pre-existing grade ≥2 hepatic\u002Frenal dysfunction or hematological toxicity (according to CTCAE v5.0 criteria) before treatment.\n* Concurrent participation in other clinical trials or concurrent use of other Chinese herbal preparations.\n* Unstable mental status or inability to cooperate with the study procedures.\n* Pregnant or lactating patients.\n* Known allergy to any component of the herbal formula used in this study.","FEMALE",{"count":55,"type":20},60,[57],"NA","1. To evaluate the preventive and therapeutic effects of Qibei Jiedu Formula on acute radiation dermatitis in breast cancer patients, including the incidence of grade 2 or higher radiation dermatitis, wound healing time, and symptom relief.\n2. To observe the safety profile of Qibei Jiedu Formula.\n3. To investigate the potential role of Qibei Jiedu Formula in improving patients' quality of life.\n4. To explore the potential mechanism of action of Qibei Jiedu Formula in preventing and treating acute radiation dermatitis in breast cancer patients through exploratory indicators such as inflammatory cytokines and skin microbiota.\n5. This study is a small-scale exploratory clinical trial. It aims to collect preliminary efficacy and safety data from 60 participants to assess the \"add-on effect\" of Qibei Jiedu Formula on top of \"standard basic care\". The results are intended for estimating effect sizes and generating hypotheses to inform future large-scale studies, not for drawing definitive conclusions.",[60,28,61],"Acute Radiation Dermatitis","Breast Cancer",[63,64,61,65],"Acute radiation dermatitis","Integrated Traditional Chinese and Western Medicine","Traditional Chinese Medicine","2026-01-27",{"date":68,"type":38},"2026-02-02",{"date":66,"type":20},{"date":71,"type":20},"2026-12-31",{"name":73,"class":45},"LI FENG",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":74},"100619963","research-on-the-extraction-of-tongue-and-facial-diagnosis-features-of-psoriasis-vulgaris-in-traditional-chinese-medicine-and-its-correlation-with-laboratory-indicators-100619963","NCT07351448","Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators","Inclusion Criteria:\n\n* Inclusion criteria for the non-psoriasis subjects: (1) Those who do not meet the Western medical diagnostic criteria for psoriasis; （2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form; Inclusion criteria for the psoriasis blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood stasis syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nInclusion criteria for the psoriasis non-blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood heat syndrome\u002Fblood dryness syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Due to various reasons, the collected tongue and facial images may be unclear or cannot be successfully monitored and analyzed; (2) For those subjects whose facial makeup or tongue coating is applied, the information obtained from tongue and facial diagnosis may be inaccurate.",true,"65 Years",{"count":84,"type":20},450,"2 Weeks","OBSERVATIONAL","Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients. Its clinical features include erythema, papules, covered with varying scales, a long course of disease, and recurrent attacks. According to traditional Chinese medicine, psoriasis is mainly characterized by blood heat syndrome, blood stasis syndrome and blood dryness syndrome, accounting for more than 90% of all syndrome types. The TCM syndrome differentiation and treatment of psoriasis also attach great importance to the transformation and evolution of TCM syndrome types. For instance, the three syndrome types of blood heat syndrome, blood stasis syndrome and blood dryness syndrome are not static and can transform into each other. For example, blood heat syndrome can develop into blood dryness syndrome as the disease progresses, blood dryness syndrome can transform into blood stasis syndrome, and blood stasis syndrome can also transform into blood heat syndrome or blood dryness syndrome. Observation is an important diagnostic method in traditional Chinese medicine. The images of tongue and face diagnosis contain a lot of important clinical information. They can objectively reflect the prosperity and decline of qi and blood in the human body, the nature of diseases, the depth of the lesion location, the prognosis of the disease, and can also reflect the physiological and pathological changes of the body. In recent years, significant progress has been made in the research of digital and intelligent technologies for tongue and facial diagnosis. Introducing objective indicators such as tongue diagnosis, facial diagnosis and pulse diagnosis into the evaluation research of diseases has become a hot topic. This project, by analyzing the clinical tongue and facial image data of patients with psoriasis vulgaris and combining it with clinical laboratory indicators, fuses and analyzes the characteristic parameters of patients' tongue and facial diagnosis with blood biochemical indicators, metabolomics and other data. This is helpful to reveal the disease occurrence pattern of patients with blood stasis type psoriasis and construct a diagnostic model for blood stasis syndrome of psoriasis. At the same time, it provides a powerful decision support tool for clinical practice and also helps deepen our understanding of the complex process of the occurrence of blood stasis type psoriasis, thereby providing a solid scientific basis for formulating precise diagnostic and treatment strategies.",[89,28,90],"Psoriasis (PsO)","Diagnosis","2026-01-12",{"date":93,"type":38},"2026-01-20",{"date":93,"type":20},{"date":96,"type":20},"2027-09-30",{"name":98,"class":45},"Shanghai Yueyang Integrated Medicine Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":74},"100597645","phase-4-fengliao-changweikang-for-diarrhea-predominant-irritable-bowel-syndrome-n-of-1-trial-100597645","NCT07061184","Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial","The Efficacy of Fengliao Changweikang Keli for Patients With Diarrhea-predominant Irritable Bowel Syndrome: Study Protocol for a Multicenter, Randomized, Placebo-controlled N-of-1 Trial","Inclusion Criteria:\n\n1. Aged between 18 and 75 years.\n2. Mild to moderate IBS-D patients, with IBS Severity Scoring System (IBS-SSS) scores of 75 to 300 points\\[14\\].\n3. Ability to complete questionnaires and provide written informed consent.\n4. Current use of IBS medications (probiotics, antibiotics, antispasmodic, antidiarrheal and neuromodulators) should be prescribed on a stable dose at least 30 days prior to enrollment, and have no plan to change the dose, diet or lifestyle.\n5. Normal blood cell count, liver function, creatinine and urea levels within the last 2 weeks.\n\nExclusion Criteria:\n\n1. History of organic gastrointestinal diseases such as inflammatory bowel disease, celiac disease and malignancy.\n2. Scores of IBS-SSS \\> 300 points or IBS-SSS \\\u003C 75 points.\n3. History of severe heart, kidney or liver diseases.\n4. Pregnant or breastfeeding.\n5. Current alcohol or drug abuse.","75 Years",{"count":108,"type":20},50,[110],"PHASE4","Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder, with characteristics of defecation related abdominal pain and diarrhea. Routine treatment strategy for IBS-D is symptom-based with unsatisfactory results, while there is a growing interest in complementary and alternative medicine such as Traditional Chinese Medicine. However, lack of high-quality evidences being the obstacle for its development.\n\nThis study aims to evaluate the efficacy of Fengliao Changweikang Keli (FLCWK) on symptoms and health-related quality of life in mild to moderate IBS-D patients.\n\nAfter 2-week run-in period, each participant will be randomized to a sequence of six 4-week double-blind treatment periods of FLCWK 8 g three times daily or placebo, separated by 2-week washout periods.",[113,28,114,115],"Irritable Bowel Syndrome - Diarrhoea","N of 1 Study Design","Efficacy and Safety","2025-07-02",{"date":118,"type":38},"2025-07-11",{"date":120,"type":20},"2025-11",{"date":122,"type":20},"2028-05",{"name":124,"class":45},"Peking Union Medical College Hospital",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":74},"100583019","neuropathic-pain-and-traditional-medicine-syndromes-in-herpes-zoster-a-cross-sectional-study-100583019","NCT06870877","Neuropathic Pain and Traditional Medicine Syndromes in Herpes Zoster: a Cross-Sectional Study","Neuropathic Pain and Traditional Medicine Syndromes in Herpes Zoster: a Cross-Sectional Study Conducted At Le Van Thinh Hospital, Vietnam","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Clinically diagnosed with Herpes Zoster (HZ) based on European Consensus Guidelines\n* Experiencing neuropathic pain associated with HZ\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* History of chronic pain conditions unrelated to HZ\n* Receiving immunosuppressive therapy or diagnosed with immunodeficiency disorders\n* Patients who had already received antiviral or analgesic treatment before evaluation\n* Patients unable or unwilling to provide informed consent",{"count":133,"type":20},80,"This study investigates the relationship between neuropathic pain characteristics and Traditional Chinese Medicine (TCM) syndromes in patients with Herpes Zoster (HZ). The study aims to integrate objective pain assessment tools, such as the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale, with TCM diagnostic classifications to enhance individualized treatment strategies. Conducted at Le Van Thinh Hospital, Vietnam, this cross-sectional study includes 80 HZ patients, assessing their pain levels and corresponding TCM syndromes. The findings will contribute to a more comprehensive approach to pain management in Herpes Zoster.",[136,28],"Herpes Zoster (HZ)","2025-03-10",{"date":139,"type":38},"2025-03-11",{"date":141,"type":20},"2025-02-28",{"date":143,"type":20},"2025-05-12",{"name":145,"class":45},"Do Thanh Sang",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":17,"studyType":86,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100583446","traditional-medicine-syndromes-in-internal-hemorrhoids-a-cross-sectional-study-100583446","NCT06876428","Traditional Medicine Syndromes in Internal Hemorrhoids: a Cross-Sectional Study","Survey on the Characteristics of Traditional Medicine Syndromes in Patients with Internal Hemorrhoids At Le Van Thinh Hospital","TMS-Hemorrhoid","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosed with internal hemorrhoids at Le Van Thinh Hospital using Goligher's classification.\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Patients with colorectal cancer or other serious gastrointestinal diseases.\n* Patients with acute inflammatory bowel disease that may interfere with the diagnosis.\n* Patients with severe chronic illnesses affecting overall health.\n* Patients unable to complete the study questionnaire due to cognitive or language barriers.",{"count":155,"type":20},150,"This study aims to investigate the characteristics of Traditional Medicine (TM) syndromes in patients diagnosed with internal hemorrhoids at Le Van Thinh Hospital. Internal hemorrhoids are a common anorectal disorder, and their classification in Traditional Medicine remains inconsistent. The study will examine the prevalence of TM syndromes in patients with internal hemorrhoids and assess the correlation between Goligher's classification and TM diagnoses.\n\nThe study will follow a cross-sectional observational design with an estimated 178 participants. Eligible patients are 18 years or older, diagnosed with internal hemorrhoids, and willing to participate. The primary outcomes include the prevalence of TM syndromes in internal hemorrhoids, severity classification according to Goligher's scale, and correlation analysis between TM syndromes and clinical severity.\n\nThe study has received approval from the Institutional Review Board (IRB) of the University of Medicine and Pharmacy at Ho Chi Minh City and will be conducted from December 2024 to April 2025 at Le Van Thinh Hospital, Vietnam.",[158,28],"Hemorrhoids Second Degree",{"date":160,"type":38},"2025-03-14",{"date":162,"type":20},"2025-08-01",{"date":164,"type":20},"2025-11-01",{"name":166,"class":45},"University of Medicine and Pharmacy at Ho Chi Minh City"]